ENDOSOLVE

Digital biomarker-based risk-stratification platform with associated wearable solutions to identify patients with pelvic conditions, such as endometriosis and subfertility, to support clinical decision-making and enhance delivery of care.

Hormonal Health lies at the heart of precision medicine. Long overlooked, the hormonal cycle in males and females is a personalized marker of health across our lifetime. OnaWave Medical’s mission is to revolutionize pelvic healthcare by harnessing the power of biological activity and digital technology

Today, individuals with endometriosis often suffer for 7 to 10 years before receiving a proper diagnosis — a delay driven by widespread symptom dismissal, misdiagnosis, and lack of access to specialized care. OnaWave Medical is working to dramatically reduce this diagnostic timeline, aiming to shift it from years to days through innovative, non-invasive technology. While diagnostic laparoscopy is still considered the gold standard for confirming endometriosis, clinical practice is increasingly moving toward a combination of advanced imaging and empirical hormonal treatment due to surgical risks, limited access to skilled providers, and high costs. However, this approach has clear limitations: hormonal treatments are effective for only 25–30% of patients, and standard imaging techniques often fail to detect peritoneal endometriosis, the most common form of the disease. Project EndoSolve seeks to close this diagnostic gap, making early, accurate, and accessible diagnosis a reality. The non-invasive, at-home adjunct test involves integrating a smartphone app, wearable sensors, and machine learning algorithms to characterize and predict endometriosis.